Sign In
Buy PLSE
$24.99
+0.710 (+2.92%)
At Close: Jun 03, 2026
Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates
06:46pm, Thursday, 19'th Feb 2026
Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.17 per share a year ago.
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results
04:05pm, Thursday, 19'th Feb 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™)
PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data
02:01pm, Monday, 09'th Feb 2026
Pulse Biosciences shares late-breaking AF data showing up to 100% procedural success, fast procedures and low adverse events for nPulse.
What's Going With Pulse Biosciences Stock On Monday?
09:18am, Monday, 09'th Feb 2026
Pulse Biosciences Inc. (NASDAQ: PLSE) stock is trading higher on continued strength after the company on Friday shared clinical data from its nPulse Cardiac Catheter first-in-human feasibility study.
Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up – Here’s Why
02:58am, Sunday, 08'th Feb 2026
Pulse Biosciences, Inc (NASDAQ: PLSE - Get Free Report) gapped up before the market opened on Friday. The stock had previously closed at $13.69, but opened at $14.95. Pulse Biosciences shares last tra
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium
07:00pm, Thursday, 05'th Feb 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™)
Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026
04:05pm, Wednesday, 04'th Feb 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA
Pulse Biosciences' nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium
07:00am, Tuesday, 03'rd Feb 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA
Pre-Market Stock Futures: Futures are trading lower as we prepare to close out the trading week. What a difference a day can make. After a blockbuster rally on Wednesday, the stock market reversed cou
Pulse Biosciences, Inc. (PLSE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
01:46am, Thursday, 15'th Jan 2026
Pulse Biosciences, Inc. (PLSE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
07:00am, Friday, 09'th Jan 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
07:00am, Tuesday, 06'th Jan 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:05pm, Monday, 29'th Dec 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 19'th Dec 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial
11:25am, Friday, 19'th Dec 2025
PLSE has secured FDA IDE approval to launch its nPulse AF ablation study.
